explore -WSS

explore

author：comprehensive 2025-10-08 18:16:22 - browse：6857

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： In venture capital firm's success, lessons for turning crisis into profit

WSS

Cognito secures funding to test medical device for Alzheimer's

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Hospitals use virtual reality to design more inclusive rooms for kids

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Do digital therapeutics have a future in medicine?

Discs beat pads, tampons for heavy menstrual flow, new study shows

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Virginia high school admissions case could be legal follow

The painfully weak evidence on taking collagen to treat arthritis

Dobbs anniversary: the lost opportunity of abortion as health care

Sage's campaign to raise awareness of postpartum depression hits a nerve

Hepatitis C has a cure — but many Americans still lack access to it

An Ebola outbreak presents a new mystery involving children

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

General Catalyst, Summa Health deal will turn on physician buy

ChatGPT in medicine: STAT answers readers' burning questions

Travel bans should be based on evidence, not politics or fear

focus

CDC launches VaccineFinder tool to locate Covid

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Covid misinformation case heads to Supreme Court

Biden praises World Series champion Astros for impact off the field during White House celebration

CDC launches VaccineFinder tool to locate Covid

An Ebola outbreak presents a new mystery involving children

explore

leisure time

knowledge

hotspot